ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

IOPIDINE 0.5%
Glaucoma
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

IOPIDINE 0.5% Rx

Generic Name and Formulations:
Apraclonidine (as HCl) 0.5%; oph soln; contains benzalkonium chloride.

Company:
Alcon Laboratories, Inc.

Therapeutic Use:

Indications for IOPIDINE 0.5%:

Short-term adjunctive therapy to reduce elevated IOP.

Adult:

Remove contact lenses; may reinsert 15min after instillation. 1–2 drops into affected eye(s) 3 times daily. Allow at least 5mins between instillation of other oph drugs.

Children:

Not established.

Contraindications:

Clonidine allergy. Concomitant MAOIs.

Warnings/Precautions:

Monitor visual fields. Severe uncontrolled cardiovascular disease, hypertension, coronary insufficiency. Recent myocardial infarction. Cerebrovascular disease. Raynaud's disease. Thromboangiitis obliterans. History of vasovagal attack. Discontinue if ocular allergic-like reactions occur. Renal or hepatic impairment: closely monitor cardiovascular parameters. Depression. May mask hypoglycemia. Pregnancy. Nursing mothers (1% soln: discontinue nursing temporarily for 1 day of use).

See Also:

IOPIDINE 1%

Pharmacological Class:

Alpha-2 agonist.

Interactions:

See Contraindications. May potentiate CNS depressants (eg, alcohol, barbiturates, opiates, sedatives, anesthetics). Caution with TCAs, β-blockers, antihypertensives, cardiac glycosides, others (eg, clonidine). Concomitant CV drugs: monitor HR, BP periodically.

Adverse Reactions:

Hyperemia, pruritus, dry mouth, itching, discomfort, tearing, dizziness, solmnolence, lid edema, blurred vision, foreign body sensation, dry eye, conjunctivitis, discharge, blanching; tachyphylaxis may develop after 1 month; also in post-laser surgery: upper lid elevation, inflammation, nasal decongestion, mydriasis, irregular HR.

Generic Availability:

YES

How Supplied:

Soln 0.5% (5mL, 10mL)—1; 1% (0.1mL)—2

Sign Up for Free e-Newsletters



CME Focus